TAGI Pharma, Inc. (TAGI Pharma), a specialty pharmaceutical company focused on the retail segment, was launched in April 2011 with the introduction of 4 generic products. TAGI Pharma is a wholly owned subsidiary of Precision Dose, Inc., which has serviced the hospital and long-term care markets with its unique line of unit dose products since 2003. TAGI Pharma is uniquely positioned in the marketplace by leveraging the Precision Dose relationships already established with hospital and long-term care customers, thereby driving demand for our products in both the retail and institutional market segments.
Today, TAGI Pharma’s product portfolio includes 8 products. Our newest addition, Codeine Sulfate Oral Solution CII, 30 mg/5mL in a 500-mL bottle, is the only FDA-approved codeine oral liquid product that does not include acetaminophen as an ingredient of the product. Codeine Sulfate is an opioid analgesic indicated for the management of mild to moderately severe pain where the use of an opioid analgesic is appropriate (a copy of the full package insert is available for review at TAGI’s website, www.tagipharma.com). We expect to launch an additional 2 products before the end of this year, and are providing for a robust product pipeline utilizing product licensing and acquisition initiatives, as well as products in various stages of development.
Key to TAGI Pharma’s success has been its customer orientation, providing program solutions specific to a customer’s needs with quality, competitively priced US-made products. At the core of our strategy is control of all sales and marketing activities, product selection, business development, and regulatory activities while outsourcing manufacturing and product development through partnerships with quality-oriented contract manufacturers and product development companies. Product selection reflects higher barriers to entry and limited competition, including controlled substances and sustained-release products, as well as products where there are opportunities in both the retail and non-retail sectors.
Our Management Team is experienced in all generic market segments, and has extensive retail relationships and product launch experience. Tom Anderson (Executive President) is leading the TAGI Pharma launch initiative and coordinates business development activities, while Kenny Harrington (VP of Sales & Marketing) is driving TAGI Pharma’s sales and marketing initiative, supported by Chris Hoffman and Michael Keiser, our National Accounts Managers. Kenny has extensive experience in both the retail and non-retail segments, and oversees our strategy to optimize the opportunities in the retail and institutional market segments, thereby positioning TAGI Pharma to meet our customers’ ever-expanding needs.
Finally, TAGI Pharma has established relationships with a network of US contract manufacturers who have excellent track records with the FDA on cGMP compliance. The product format capabilities of these manufacturers encompass tablets, capsules, liquids, and creams and ointments, as well as Schedule II to V drugs. We work with our suppliers as strategic partners in our product development program to ensure that our products can meet the ruggedness of a production environment within specified quality parameters. Since our contract manufacturers are US-based, TAGI Pharma’s supply chain is much shorter and more reliable than competitors sourcing their products from non-US manufacturing sites, thereby ensuring excellent service levels for customers from our Midwest distribution center.
For more information, please visit www.tagipharma.com.